HAIFA, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), an innovator in the development of leading cell-based technologies for various indications, congratulates Mesoblast Ltd. (“Mesoblast”) and its Chief Executive Officer, Silviu Itescu, on the U.S. Food and Drug Administration (the “FDA”) approval of the first MSC-based therapy for steroid-refractory acute... Read More

HAIFA, Israel, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) ("Pluri" or the “Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that its PluriCDMO ™ business, launched earlier this year, has been shortlisted for the CDMO of the Year Award by the prestigious Advanced Therapies Awards... Read More

HAIFA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that it is assessing its readiness to initiate mass production of PLX-R18, a novel potential treatment for hematopoietic complications of the acute radiation... Read More

HAIFA, ISRAEL / ACCESSWIRE / November 12, 2024 / Pluri Inc. (NASDAQ:PLUR), a leading biotechnology company that offers cell-based solutions for various industries. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation. Event: Q4 Investor Summit Presentation Time: 9:00am - 9:30am ET Location: https://www.webcaster4.com/Webcast/Page/3075/51643 The theme is 40 micro-cap companies... Read More

The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen , Head of the laboratory of tumor immunology and immunotherapy at Bar-Ilan University MAIT cells hold immense potential for immunotherapy and the treatment of solid tumors compared to conventional T-cells, but their expansion has been a challenge until Pluri announced its proprietary MAIT... Read More

HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd. (TASE: KDST), a clinical stage biotechnology company developing therapeutic cells for ALS and... Read More

HAIFA, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), which transforms cells into solutions that promote global wellbeing and sustainability, has announced a strategic proof of concept (“POC”) agreement with a leading international agriculture corporation. The agreement is intended to boost the global vegetable product supply,... Read More

$10 million funding round from U.S. and EU strategic investors, will accelerate growth and empower efficient cultivated meat, fish and seafood production at global scale, potentially tackling significant scalability challenges faced by the cultivated food industry Round led by global corporates with significant equipment, manufacturing, supply chain, and product development experience, alongside a second investment from... Read More

As part of Pluri’s previously announced $4.2 million 3-year contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the option for the second year of the contract has been exercised to fund manufacturing, in-vitro, and in-vivo studies of Pluri’s cell therapy PLX-R18 is designed to be a first in class, effective treatment for ionizing radiation injuries that could be anticipated in the wake of a... Read More

New production process will be developed based on Pluri’s proprietary 3D cell expansion technology Human breast milk oligosaccharides are known to shape the gut microbiota and thus provide health benefits to adults Global elderly nutrition market is valued at $25.2 billion, estimated to reach $39.7 billion in less than 10 years HAIFA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:... Read More

Placental Mucosal Associated Invariant T (MAIT) cells are unique unconventional immune T cells which are particularly suitable for the treatment of solid tumors, a significant unmet medical need MAIT cells offer unique advantages compared to conventional T cells MAIT cells hold immense potential for immunotherapy, but their expansion has been a challenge thus far. Pluri, leveraging two decades of cell expertise, has overcome... Read More

Pluri’s patent enables mass-scale production of immune cell therapies New patented technology is applicable for the expansion of a variety of immune cells Technology sets stage for potential immune cell therapy advancements and targets an estimated total addressable market of $11.66 billion by 2030 HAIFA, Israel, April 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company, Pluri Inc . (Nasdaq:PLUR) (TASE:PLUR) (“Pluri”... Read More

HAIFA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Pluri Inc . (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced leadership from its business verticals will be presenting at, and participating in, the following conferences: Conference: MIW, Germany-Israel Technology Date: April 10, 2024... Read More

HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), a leading biotechnology company that transforms cells into solutions, today announced that a reverse share split of the Company’s issued and outstanding common shares, par value $0.00001 per share (the “Common Shares”) at a ratio of 1-for-8 is expected to be implemented at market open on April 1, 2024. The... Read More

International Coffee Organization (ICO) Market Report published o n March 7, 2024 highlights alarming price instability challenging the coffee industry According to the report, adverse weather conditions, first noted in 2022 and continuing into 2023, will have a negative impact on the outlook for coffee in 2024 Pluri’s cell-based coffee’s innovative process mimics nature without exploiting it, ensuring consistent quality and... Read More

HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced its participation in the following upcoming conferences. Conference: Bio-Europe Spring Date: March 18-20, 2024 Location: Barcelona Pluri’s Chief Business Development... Read More

HAIFA, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today announced that its CDMO division (PluriCDMO™) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.... Read More

HAIFA, Israel, March 11, 2024 (GLOBE NEWSWIRE) -- In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company") today announced an important expansion to its intellectual property portfolio with a new patent approval, that is designed to reshape the agricultural technology landscape. The patent titled “A System for 3D Cultivation of Plant Cells... Read More

HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company’s Advisory Board. Having served in public-service positions in Washington, D.C., followed by a successful decade in... Read More

Growing pipeline of industry-specific new potential products, services, collaborations and partnerships through PluriAgtech, PluriCDMO, PluriHealth, and PluriFood Recent achievements include: new cell-based coffee business; new agtech division and first partners; new Contract Development and Manufacturing Organization division; $4.2 million Contract with the U.S. NIH and new partnership with Bar-Ilan University Landmark... Read More

Pluri to leverage its proprietary 3D technology platform to develop cell-based products for the coffee industry under its new business vertical PluriAgtech The rapidly growing $130 billion coffee industry is at risk as global warming reduces the availability of viable land for coffee cultivation by up to 50% by 2050 C ompared... Read More

Pluri, an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) division. PluriCDMO ™ will help innovative companies develop and manufacture life-changing therapies within the rapidly growing $5.2... Read More

Agreement signed following positive pre-clinical data demonstrating a one-time treatment with PLX-PAD significantly increased neurogenesis, offering immediate, long-term therapeutic effect in treating cocaine addiction There are no FDA-approved medications to treat cocaine addiction, a severely unmet need as demand for... Read More

Results support the development of PLX-R18 for hematologic acute radiation syndrome (H-ARS), currently under a $4.2 million contract with the U.S. National Institutes of Health PLX-R18 has the advantage of being an off-the-shelf product with no risk of graft vs. host disease (GvHD), reducing the need for blood product transfusions HAIFA, Israel, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR)... Read More

HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the appointment of Lorne Abony to the Company’s Board of Directors, effective as of July 11, 2023. Abony is a successful entrepreneur who has decades of experience building and scaling... Read More

Pluri's cell therapy is designed to be the first in class, effective treatment for ionizing radiation poisoning in the event of a large-scale nuclear incident. The work specified by the contract is based on communications with the FDA and will enable Pluri to make significant progress toward marketing approval for PLX-R18.... Read More

Breakthrough system substantially increases cell production, with the potential to reach much higher productivity driven by platform’s significant scalability Flexible, industrial scale cell production to power a broad range of cell-based products for industries including pharma, biologics, foodtech and cellular agri-tech... Read More

HAIFA, Israel, March 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, announced today that Israel’s Ministry of Labor, Social Affairs and Social Services has selected Pluri as the winner of the 2022 Egalitarian Employment Award in the Large Company category. Pluri was selected for this highly... Read More

Milestones over the last year include launch of new Company strategy, joint venture with Tnuva Group in the field of cultivated meat and additional biologics technology partnership; Joint venture with Tnuva reaches proof of concept and continues working toward product launch; Pluri is actively exploring new partnerships and poised to capitalize on further collaborations in the year ahead. HAIFA, Israel, Dec. 22, 2022 (GLOBE... Read More

HAIFA, Israel, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, announced today that it has signed securities purchase agreements with domestic and non-U.S. investors for the sale of an aggregate of 7,885,900 of the Company’s common shares and warrants to purchase up to an aggregate of 7,885,900 of the Company’s common shares. On December... Read More

Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”)(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced its participation in three upcoming conferences. Conference: CPHI Frankfurt Date: November 1-3, 2022 Location: Frankfurt, Germany Pluri’s Chief Commercial Officer, Nimrod Bar Zvi , and VP Business Development, Efrat Kaduri , will attend CPHI Frankfurt. CPHI... Read More

New company strategy will reduce cash burn by approximately 30%, with $56M in cash on consolidated balance sheet Leading European manufacturer of active pharmaceutical ingredients (APIs) to use Pluri’s 3D cell expansion technology, which aims to revolutionize the production of biologics by enabling cost-effective, sustainable, and cruelty-free ingredients Agreement marks Pluri’s second tech collaboration following joint... Read More

Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced that a €7.5 million non-dilutive grant from the European Union’s Horizon Europe program has been awarded to PROTO (Advanced PeRsOnalized Therapies for Osteoarthritis), an international collaboration led by Charité, Berlin Institute of Health Center for... Read More